FDA Clarifies Review Criteria by Publicly Releasing Summaries of Patient Listening Sessions, Including Leqembi and Sevasemten
FDA's Patient Engagement Initiative and Standardization Efforts
The U.S. Food and Drug Administration (FDA) has released summaries of its 'Patient Listening Sessions,' which gather unmet medical needs from patient organizations and caregivers. This is a federal-level initiative to refine the Patient-Focused Drug Development (PFDD) guidelines, which aim to evaluate the quality of life of patients during the new drug approval process. As a result, the inclusion of Patient-Reported Outcomes (PROs) is becoming a key criterion for review by the FDA, the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan.
New Milestone in the Development of a Treatment for Becker Muscular Dystrophy
During the Becker Muscular Dystrophy (BMD) session held on January 14, 2026, patients strongly emphasized the need to preserve motor function. Edgewise Therapeutics (EWTX) is developing Sevasemten (EDG-5506), a fast skeletal muscle myosin inhibitor, and is conducting Phase 2 (CANYON/LYNX) and Phase 3 (GRAND CANYON) clinical trials, incorporating patient needs into the evaluation. With Sarepta Therapeutics' (SRPT) Elevidys (delandistrogene moxeparvovec-rokl) already on the market, Sevasemten is expected to be a significant innovation in the dystrophinopathy market, which is projected to grow to $8.5 billion by 2030.
Enhanced Safety Standards and Market Competition for New Alzheimer's Drugs
The session on Alzheimer's Disease (AD) related to the APOE e4 gene discussed in detail the guidelines for proactive monitoring of Amyloid-Related Imaging Abnormalities (ARIA). Eisai (ESALY) and Biogen (BIIB)'s Leqembi (lecanemab), which targets amyloid beta protofibrils, received unanimous support (6-0) from the advisory committee (AdComm) on June 9, 2023, and was approved on July 6. Eli Lilly (LLY)'s Kisunla (donanemab), which targets N3pG amyloid beta, also received a positive recommendation (11-0) from the advisory committee on June 10, 2024, and was approved on July 2. With the inclusion of APOE e4 adverse event information in the labels of these marketed drugs, ease of adverse event management is becoming a major factor in market share.
Strategic Partnerships and Deal Structures in the Biopharmaceutical Industry
Global pharmaceutical companies are entering into partnerships worth billions of dollars to share development costs. In the case of the co-development of Leqembi, Eisai and Biogen share profits and losses on a 50/50 basis and jointly support clinical trials and commercialization. This mega-deal structure emphasizes milestone payments and royalties over upfront payments, reflecting a rational venture capital (VC) model that allocates funds based on development progress. This structure is expected to become the norm for future deals in the brain disease and rare disease markets.
The FDA's release of summaries from its patient listening sessions serves as a milestone in integrating Patient-Reported Outcomes (PROs) as quantitative indicators for regulatory approval, thereby increasing the probability of success in clinical trial design. In the short term, Edgewise Therapeutics' (EWTX) Phase 2/3 Sevasemten trials provide functional assessment variables that could give it an advantage over Sarepta's (SRPT) Elevidys in the Becker Muscular Dystrophy market. In the medium to long term, the market share competition between Eisai (ESALY) and Biogen (BIIB)'s Leqembi and Eli Lilly (LLY)'s Kisunla in the Alzheimer's disease market, which is expected to grow to $15 billion annually, will be determined by the standard for managing ARIA safety in patients with the APOE e4 genotype. This suggests that diversifying clinical evaluation indicators and establishing a global standardization collaboration system will be key factors in corporate valuation for biotech researchers and investors.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries